**Author Information** An event is serious (FDA MedWatch definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* requires intervention to prevent permanent impairment or damage

A 56-year-old man developed paralysis, respiratory failure and adult respiratory distress syndrome following accidental intrathecal vincristine admission.

The man, who had a history of leukaemia, hepatitis C virus (HCV) and HIV, accidentally received vincristine 1.3mg intrathecally instead of methotrexate. He was started on continuous external ventricular drainage (EVD) and was continued for 5 days. He was additionally treated with pyridoxine, folinic acid and cyanocobalamin. On day 8, he developed paralysis, respiratory failure and adult respiratory distress syndrome (ARDS). He required a respiratory support. However, he died on day 31. Vincristine level of 4.9 mg/L was observed prior to the EVD, which became undetectable from day 2.

**Author comment:** *\"We report a fatal case of analytically confirmed intrathecal accidental administration of vincristine.\" \" Inadvertent intrathecal administration produces ascending paralysis and severe neurotoxicity that can progress to respiratory failure and coma.\"*
